Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Deferred Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Current Deferred Revenue for 12 consecutive years, with $399000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 34.7% to $399000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $399000.0 through Dec 2025, down 34.7% year-over-year, with the annual reading at $399000.0 for FY2025, 34.7% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $399000.0 at Niagen Bioscience, up from $292000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $611000.0 in Q4 2024, with the low at $141000.0 in Q1 2022.
  • Average Current Deferred Revenue over 5 years is $223789.5, with a median of $184000.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 42.09% in 2021, then skyrocketed 213.33% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $161000.0 in 2021, then dropped by 2.48% to $157000.0 in 2022, then grew by 24.2% to $195000.0 in 2023, then surged by 213.33% to $611000.0 in 2024, then tumbled by 34.7% to $399000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $399000.0, $292000.0, and $303000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.